The Incidence of Extended-spectrum β-lactamase (ESBL) Klebsiella Pneumonia in Patient on Renal Replacement Therapy

June 4, 2012 updated by: Hoseok Koo, Inje University
The prevalence of ESBL Klebsiella pneumonia was higher in patient with renal replacement therapy.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Actual)

1289

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Korea, Republic of
    • Je dong 2ga, Jung gu
      • Seoul, Je dong 2ga, Jung gu, Korea, Republic of, 100-032
        • Inje University Seoul Paik hospital Instituional Board Review

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 79 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

The patients had admitted in single center

Description

Inclusion Criteria:

  • The age of patient was between 18 yrs and 79 yrs.
  • The patient who showed Klebsiella pneumonia in 1st culture result of any site during hospitalization

Exclusion Criteria:

  • The level of serum albumin was below 2.0 or over 5.0
  • The level of AST or ALT was 2 times of normal level or the level of bilirubin was over 2.0 mg/dL during 1month.
  • The level of Body mass index was below 15 or over 30
  • Pregnancy

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Time Perspectives: Retrospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
ESBL(+) Klebsiella pneumonia
All the patient who's the culture result showed ESBL(+) Klebsiella pneumonia in any site during hospitalization
Other: renal replacement therapy
renal replacement therapy : hemodialysis and/or CRRT(continuous renal replacement therapy )
ESBL(-) Klebsiella pneumonia
All the patient who's the culture result showed ESBL(-) Klebsiella pneumonia in any site during hospitalization
Other: renal replacement therapy
renal replacement therapy : hemodialysis and/or CRRT(continuous renal replacement therapy )

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The prevalence of ESBL Klebsiella pneumonia in renal replacement therapy
Time Frame: During hospitalization
The prevalence of ESBL Klebsiella pneumonia in renal replacement therapy during hospitalization up to 8 years (from 2004 to 2011)
During hospitalization

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The prevalence of ESBL Klebsiella pneumonia in patient with pneumonia and renal replacement therapy
Time Frame: during hospitalization
The prevalence of ESBL Klebsiella pneumoina in patient with pneumonia and renal replacement therapy during hospitalization up to 8 years (from 2004 to 2011)
during hospitalization

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Inje University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

March 1, 2012

Study Completion (Actual)

May 1, 2012

Study Registration Dates

First Submitted

May 29, 2012

First Submitted That Met QC Criteria

June 4, 2012

First Posted (Estimate)

June 5, 2012

Study Record Updates

Last Update Posted (Estimate)

June 5, 2012

Last Update Submitted That Met QC Criteria

June 4, 2012

Last Verified

June 1, 2012

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • ESBL 2012-1

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on End-stage Renal Disease

Clinical Trials on renal replacement therapy

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Belgium

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe